Michetti P
Division of Gastroenterology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA.
J Gastroenterol. 1998;33 Suppl 10:66-8.
The demonstration that oral immunization with lysates of Helicobacter or with Helicobacter pylori urease can protect mice against H. felis infection opened the field of vaccine development against Helicobacter infections. More recently, the same antigen preparations were used successfully as a therapeutic vaccine able to cure the infection, and additional protective antigens were identified. Evidence from animal studies suggests that protection is medicated by mucosal antibodies, in association with a T helper type 2 cell cellular immune response. Vaccine adjuvants, delivery systems, and therapeutic vaccination are likely to be the areas of major progress in the future.
用幽门螺杆菌裂解物或幽门螺杆菌尿素酶进行口服免疫可保护小鼠免受猫螺杆菌感染,这一发现开启了抗幽门螺杆菌感染疫苗研发领域。最近,同样的抗原制剂成功用作治疗性疫苗治愈了感染,并且还鉴定出了其他保护性抗原。动物研究证据表明,保护作用是由黏膜抗体介导的,并伴有2型辅助性T细胞细胞免疫反应。疫苗佐剂、递送系统和治疗性疫苗接种可能是未来取得重大进展的领域。